PP
GSK icon

Pegasus Partners’s GSK GSK Stock Holding History

Pegasus Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,486
Closed -$219K – 150
2018
Q1 		$219K Sell
4,486
-12,181
-73% -$567K 0.05% 139
2017
Q4 		$739K Sell
16,667
-21,785
-57% -$1.01M 0.15% 128
2017
Q3 		$1.95M Sell
38,452
-14,040
-27% -$712K 0.45% 70
2017
Q2 		$2.83M Sell
52,492
-773
-1% -$41.2K 0.75% 47
2017
Q1 		$2.81M Buy
53,265
+1,547
+3% +$78.5K 1.16% 18
2016
Q4 		$2.49M Sell
51,718
-79,187
-60% -$3.91M 1.1% 23
2016
Q3 		$7.06M Sell
130,905
-1,811
-1% -$99.3K 3.34% 4
2016
Q2 		$7.19M Sell
132,716
-5,104
-4% -$269K 3.72% 3
2016
Q1 		$6.99M Sell
137,820
-39,360
-22% -$1.96M 3.79% 3
2015
Q4 		$8.94M Sell
177,180
-6,016
-3% -$307K 4.48% 3
2015
Q3 		$8.8M Buy
183,196
+76
+0% +$3.96K 5% 3
2015
Q2 		$9.53M Buy
+183,120
New +$10.3M 4.2% 5

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pegasus Partners's GSK Position: Q2 2018 in Review

Pegasus Partners sold out of GSK (GSK) in Q2 2018, closing a stake of 4,486 shares — an estimated $219K sold.

Pegasus Partners first reported a position in GSK in Q2 2015 and held it in 12 quarters. The position peaked at $9.53M in Q2 2015. 787 funds tracked by Wall St. Rank hold GSK as of Q2 2018.

  • Pegasus Partners reported no remaining GSK position as of Q2 2018 after selling out during the quarter.
  • Pegasus Partners sold 4,486 GSK shares in Q2 2018, an estimated $219K.
  • Pegasus Partners first reported a position in GSK in Q2 2015 and held it in 12 quarters.
  • Pegasus Partners's GSK position peaked at $9.53M in Q2 2015.
  • 787 funds tracked by Wall St. Rank held GSK as of Q2 2018.

Based on Pegasus Partners's 13F filing for Q2 2018, filed 27 Jul 2018.